SCHEMBL4397656

SCHEMBL4397656

COCN(Cc1ccc(C(=O)Nc2ccccc2NC(=O)OC(C)(C)C)cc1)C(=O)Nc1ccc2c(c1)CCC2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.45
MAPT P10636 5/20 0.45
ALDH1A1 P00352 4/20 0.45
TP53 P04637 3/20 0.45
GAA P10253 2/20 0.45
HPGD P15428 2/20 0.45
KDM4E B2RXH2 1/20 0.45
NPC1 O15118 8/20 0.44
RAB9A P51151 8/20 0.44
NFKB1 P19838 3/20 0.44
NFKB2 Q00653 3/20 0.44
RELA Q04206 3/20 0.44
HTT P42858 2/20 0.44
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
LMNA P02545 2/20 0.42
HDAC1 Q13547 3/20 0.41
HDAC6 Q9UBN7 2/20 0.41
TRPV1 Q8NER1 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12051529 0.93 HDAC1 (0.51) SMN1; SMN2MAPTALDH1A1TP53GAA
SCHEMBL2493852 0.89 HDAC1 (0.48) SMN1; SMN2MAPTALDH1A1TP53GAA
SCHEMBL3835490 0.89 KMT2A (0.43) SMN1; SMN2MAPTALDH1A1TP53GAA
SCHEMBL3832641 0.89 NPC1 (0.42) SMN1; SMN2MAPTALDH1A1TP53GAA
SCHEMBL3832874 0.88 MCHR1 (0.43) SMN1; SMN2MAPTALDH1A1TP53GAA
SCHEMBL3832811 0.88 HDAC1 (0.49) SMN1; SMN2MAPTALDH1A1TP53GAA
SCHEMBL3835293 0.88 KMT2A (0.46) SMN1; SMN2MAPTALDH1A1TP53GAA
SCHEMBL3834158 0.87 HDAC1 (0.42) SMN1; SMN2MAPTALDH1A1TP53GAA
SCHEMBL3832626 0.84 NPC1 (0.51) MAPTALDH1A1HPGDKDM4ENPC1
SCHEMBL2474642 0.83 MAPT (0.49) MAPTALDH1A1TP53GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076332-B2 N- (2-aminophenyl) benzamide derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-12-13 US disclosed
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306077-A1 NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE UACA, SLC14A1, ARG2 SMN1; SMN2 4637/4885MAPT 1576/4885ALDH1A1 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.